Oncology

#Collaboration #Innovent #Oncology #Pfizer

Pfizer and Innovent Biologics ink $10.5 billion oncology deal

Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion.  The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads and multi-specific antibodies… Read More

#Business & Investment #News #Trending News

Fast track concept
#Accelerated assessment #Oncology #Osteosarcoma #Paediatrics #Regulatory

The case for accelerated approval in recurrent osteosarcoma

Introduction In an age where novel biotechnology products are being developed on a much larger and more rapid scale at significantly higher costs and risks than ever before, it is important that this urgency is maintained through to patient access. Owing to the broad reach and the mass adoption of… Read More

#Cancer Research #Exclusive Content #Regulatory

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (18 – 22 May)

News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW.    This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health.    The… Read More

#News

Cancer cells
#Cancer research #Drug discovery #eBook #Immunotherapy #Oncology

DDW eBook: Breakthroughs & expertise in cancer research

This eBook, sponsored by Sartorius, explores the latest developments in cancer research and why it matters, advances in immunotherapy, unlocking new frontiers in cancer research and ways that experts are driving the industry.  Download this exclusive eBook to learn more about:    Autotaxin… Read More

#News

Cancer Research eBook
#Cancer research #Drug discovery #eBook #Immunotherapy #Oncology

Breakthroughs & expertise in cancer research

This eBook, sponsored by Sartorius, explores the latest developments in cancer research and why it matters, advances in immunotherapy, unlocking new frontiers in cancer research and ways that experts are driving the industry.

#DDW eBooks #Intelligence

Doctor holding x-ray
#Clinical trial design #Clinical trials #Oncology #Osteosarcoma #Paediatrics

Novel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs

Introduction Rare diseases, as classified by the FDA and EMA, are conditions that affect fewer than 200,00 people in the US1 or fewer than five in 10,000 people in the EU2. Because of these small populations, rare diseases often face unique – and some respects potentially more significant – hurdles… Read More

#Exclusive Content

#AI #Antimicrobial resistance (AMR) #Drug discovery #Genomics #India #Oncology

India: Who should we be watching in the drug discovery space?

Diana Turner takes a look at drug discovery in India, a country making the shift from scale to innovation.  While the Indian pharmaceuticals sector has long held a key global position as a centre for generics development and manufacturing, the country is beginning to make a significant name for itself as a… Read More

#Exclusive Content

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News

Cancer research
#Cancer research #Drug discovery #In Focus Report #Oncology

New InFocus eReport: Advances in cancer research

Although the cancer mortality rate has dropped by 34% since its peak in 1991, the incidence continues to increase for many common cancers. This new DDW InFocus eReport, sponsored by Evotec, provides a full understanding of the current market for oncology drug discovery and the areas… Read More

#Cancer Research #News

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

DDW Highlights: 12 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the FDA advanced an initiative to implement real-time clinical trials. Elsewhere, UCB made… Read More

#Podcasts

#CellCentric #Fundraising #Oncology #T cell engagers

CellCentric raises $220m to advance trials of oral myeloma drug

CellCentric has completed an oversubscribed $220 million Series D financing led by Venrock Healthcare Capital Partners, with participation from new and existing investors.  The proceeds will support clinical trials for multiple myeloma therapy inobrodib. These will include continued enrolment of the company’s Phase II DOMMINO-1 study and initiation of the… Read More

#Business & Investment #News #Trending News

#Artificial intelligence (AI) #AstraZeneca #Collaboration #Immunai #Oncology

AstraZeneca expands AI oncology collaboration with Immunai

AstraZeneca and Immunai have expanded their collaboration, extending a multi-year collaboration in oncology clinical development through 2027.  Under the new deal, Immunai is eligible to receive up to $37.5 million over 2026-2027. It marks the third expansion of the partnership between the two companies, building on previous collaborations in oncology… Read More

#Business & Investment #News

Medical professional examining mammogram
#Breast cancer #Cancer drug targets #Institute of Cancer Research #Oncology

Research suggests new treatment pathway for triple-negative breast cancers

New research has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC).  The study, published in Genome Medicine and funded by the charity Breast Cancer Now and others, pinpoints important genes that could be targeted by new drugs. Read More

#Cancer Research #Editor's Choice #News

#3D modelling #Drug development #Oncology #Organoids

Rewriting the Oncology Playbook

Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology.  Drug development is a complex, costly, and time-consuming process with a high failure rate. Effective cancer therapy development in particular, remains challenging with only 3.4% of drugs entering clinical trials between 2000 and 2015 reaching… Read More

#Exclusive Content